GSK Bio
NEWS
Immutep Limited announces that it will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
Companies from across the globe share updates on their business and pipelines.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain.
Microsoft announced that Emma Walmsley, chief executive officer of GlaxoSmithKline, had been nominated to the company’s board of directors.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the United States, the company said.
A therapy that leads to fewer asthma attacks while reducing the need for corticosteroids is ideal, especially for those who continue to have severe symptoms while using traditional therapies. That’s where biologics come in.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
With more than 25 years experience in chemotherapeutic products and cancer vaccines, she will lead the ongoing phase I/II trial in NSCLC
JOBS
IN THE PRESS